Benutzer: Gast  Login
Titel:

Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.

Dokumenttyp:
Journal Article
Autor(en):
Haas, S
Abstract:
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE), prevention of stroke in patients with atrial fibrillation (AF) and secondary prevention in patients with acute coronary syndrome (ACS). There is a clinical need for novel anticoagulants offering improvements over current standard of care, such as fixed oral dosing and no need for routine monitoring. Rivaroxaban, an oral, once-daily, direct Factor Xa inhibitor, has recently completed the RECORD phase...     »
Zeitschriftentitel:
Eur J Haematol
Jahr:
2009
Band / Volume:
82
Heft / Issue:
5
Seitenangaben Beitrag:
339-49
Sprache:
eng
Volltext / DOI:
doi:10.1111/j.1600-0609.2009.01230.x
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/19187276
Print-ISSN:
0902-4441
TUM Einrichtung:
Institut für Experimentelle Onkologie und Therapieforschung
 BibTeX